A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

Brief summary (registry, in English)

Stage 1: To evaluate the efficacy, safety, PK and PD of telitacicept 160 mg and 240 mg administered as a subcutaneous injection via prefilled syringes (PFS) weekly for 52 weeks in adult patients with active SLE while receiving SOC treatment. Stage 2: To evaluate the efficacy of telitacicept at Week 52 in adult subjects with moderately to severely active SLE with an inadequate response to SoC therapy.

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 146
• 32 sites in 6 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (32)

Sites in registry order. Save your city in your profile to sort them by distance.